Company Greenwich LifeSciences, Inc.

GLSI

US3968791083

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
12.62 ^USD	-3.96%		-3.30%	+19.96%

Apr. 15	Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 will be delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. The Company's Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver certain immune system components to inhibit the spread of cancer.

Number of employees: 5

Managers	Title	Age	Since
Eric Rothe FOU	Founder	49	06-08-28
Snehal Patel CEO	Chief Executive Officer	60	10-01-31
David B. McWilliams CHM	Chairman	81	09-01-31
F. Joseph Daugherty CTO	Chief Tech/Sci/R&D Officer	74	19-08-31
Jaye L. Thompson CTO	Chief Tech/Sci/R&D Officer	58	19-08-31
Christine T. Fischette PRN	Corporate Officer/Principal	-	21-04-18

Members of the board	Title	Age	Since
David B. McWilliams CHM	Chairman	81	09-01-31
F. Joseph Daugherty CTO	Chief Tech/Sci/R&D Officer	74	19-08-31
Snehal Patel CEO	Chief Executive Officer	60	10-01-31
Eric Rothe FOU	Founder	49	06-08-28
Kenneth Hallock BRD	Director/Board Member	76	19-08-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	12,878,409	6,106,584 ( 47.42 %)	0	47.42 %

Name	Equities	%	Valuation
Snehal Patel 41.65 %	5,350,777	41.65 %	107 M $
David B. McWilliams 4.828 %	620,327	4.828 %	12 M $
Kenneth Hallock 3.093 %	397,333	3.093 %	8 M $
Eric Rothe 2.438 %	313,255	2.438 %	6 M $
Jaye L. Thompson 2.026 %	260,348	2.026 %	5 M $
Vanguard Global Advisers LLC 1.725 %	221,682	1.725 %	4 M $
F. Joseph Daugherty 0.7015 %	90,133	0.7015 %	2 M $
Degroof Petercam Asset Services SA 0.6771 %	87,000	0.6771 %	2 M $
BlackRock Institutional Trust Co. NA 0.4359 %	56,010	0.4359 %	1 M $
Ameriprise Financial Services LLC 0.4175 %	53,647	0.4175 %	1 M $

Greenwich LifeSciences, Inc.

3992 Bluebonnet Drive Building 14

77477, Stafford

http://www.greenwichlifesciences.com

address Greenwich LifeSciences, Inc.(GLSI)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

12.62 USD

Average target price

36 USD

Spread / Average Target

+185.26%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
GREENWICH LIFESCIENCES, INC.	+19.96%	163M
CSL LIMITED	-2.86%	87.31B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	40.86B
BIOGEN INC.	-21.94%	29.36B
UCB	+56.46%	24.49B
BIOMARIN PHARMACEUTICAL INC.	-5.41%	17.31B
INCYTE CORPORATION	-17.60%	11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.96%	11.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.23%	11.26B
SWEDISH ORPHAN BIOVITRUM AB	+7.27%	8.31B

Biopharmaceuticals